Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-10-11 04:43Group 1 - The company expects a net profit attributable to shareholders of the parent company for Q3 2025 to be between 130 million and 140 million yuan, representing an increase of 6.91 million to 16.91 million yuan compared to the same period last year, with a year-on-year growth of 5.62% to 13.74% [3] - The expected net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses is also projected to be between 130 million and 140 million yuan, with an increase of 4.71 million to 14.71 million yuan compared to the same period last year, reflecting a year-on-year growth of 3.76% to 11.74% [3] - The performance forecast is based on preliminary calculations by the company's financial department and has not been audited by registered accountants [4] Group 2 - In the same period last year, the company's total profit was 128.28 million yuan, with a net profit attributable to shareholders of the parent company of 123.09 million yuan, and a net profit after deducting non-recurring gains and losses of 125.29 million yuan, with basic earnings per share of 0.58 yuan [5] - The company has implemented a business philosophy of "time leading, technology leading," which has contributed to the steady growth of net profit during the reporting period [6]